Clinical trials: Vascular
Myocardial Infarction
A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO4905417 in patients with non ST-elevation myocardial infarction (Non-STEMI) undergoing percutaneous coronary intervention (PCI).
- Trial name
- NCT01327183
- Testing
- Percutaneous Coronary Intervention (PCI), RO4905417
- Where
- 66 sites in United States, Canada and 2 more
- Volunteers
- 532 people
- Sponsor
- Hoffmann-La Roche
Acute Myocardial Infarction, STEMI
A Study of Acute Myocardial Infarction Using FDY-5301
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of three dose levels of FDY-5301 compared to placebo in STEMI patients undergoing PCI.
- Trial name
- NCT03470441
- Testing
- FDY-5301
- Where
- 23 sites in United States, Hungary and 2 more
- Volunteers
- 120 people
- Sponsor
- Faraday Pharmaceuticals, Inc.
Intracerebral Hemorrhage
Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system. The primary objective was to assess the safety and tolerability of NXY-059 compared to placebo.
- Trial name
- NCT00075959
- Testing
- NXY-059
- Where
- 64 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Stable Angina, Unstable Angina
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
A multi-center, prospective, consecutive enrolled, observational registry. The population being studied includes all patients undergoing treatment of "de novo" lesions in native coronary vessels, saphenous vein graft and/or…
- Conditions
- Stable Angina, Unstable Angina, ACS - Acute Coronary Syndrome, STEMI
- Trial name
- eCOBRA (NCT03103620)
- Testing
- COBRA PzF Coronary Stent System
- Where
- 18 sites in France
- Volunteers
- 1,027 people
- Sponsor
- CeloNova BioSciences, Inc.
Atherosclerosis, Ischemia
Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)
This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in participants with established atherosclerotic disease who are enrolled into the TRA 2°P - TIMI 50 Study (P04737) (NCT00526474).
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00617123
- Testing
- Vorapaxar 2.5 mg
- Volunteers
- 258 people
- Sponsor
- Merck Sharp & Dohme LLC
Venous Thromboembolism, Children Under 2 Years
A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE).
- Trial name
- XAPAEDUS (NCT05900388)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care (SOC)
- Where
- 4 sites in Denmark, France and 2 more
- Volunteers
- 850 people
- Sponsor
- Bayer
Vascular Diseases
EndovascuLar RegIstry Evaluating SafeTy, Efficacy and Patient Comfort (ELITE)
A single-center, prospective, cohort analysis of the Femoral Introducer Sheath and Hemostasis (FISH) vascular closure device will study 100 consecutive patients on which the device will be used to close the femoral artery after…
- Trial name
- ELITE (NCT03412942)
- Testing
- FISH SP
- Where
- 3 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Morris Innovative Incorporated
Venous Ulcer of Leg
Intravascular Ultrasound-Guided Intervention for Venous Leg Ulcers (IGuideU)
This clinical study is a global, prospective, multi-center, randomized controlled trial to determine if the use of intravascular ultrasound (IVUS) as an adjunctive imaging modality and as an interventional treatment guide will…
- Trial name
- IGuideU (NCT04696354)
- Testing
- IVUS, Continued Compression Therapy/Stockings
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 12 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Hypertension
Telmisartan and Amlodipine Versus Monocomponent Tablets
This study will be an open-label, randomized, two-treatment, two-period, two-sequence crossover study to evaluate the bioequivalence of the amlodipine component of Boehringer Ingelheim Pharma GmbH \& Co.
- Trial name
- NCT01278797
- Testing
- Telmisartan/Amlodipine Combination Tablet, Amlodipine Monocomponent
- Where
- Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Stroke
Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke
The objective of this study is to assess the safety, tolerability and pharmacokinetic characteristics of BIII 890 after intravenous infusion in acute ischemic stroke patients.
- Trial name
- NCT02251197
- Testing
- BIII 890 CL
- Volunteers
- 97 people
- Sponsor
- Boehringer Ingelheim
Hypercholesterolemia, Coronary Heart Disease
Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)
In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l.
- Trial name
- NCT00396110
- Volunteers
- 3,889 people
- Sponsor
- AstraZeneca
Multiple Myeloma
Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma
The purpose of the study is to evaluate the safety and effectiveness of melphalan for injection for autologous stem cell transplant in multiple myeloma
- Trial name
- MM (NCT01572688)
- Testing
- Melphalan
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shandong Lanjin Pharmaceuticals Co.,Ltd
Transient Ischemic Attack, Thromboembolic Stroke
Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZ™ and the EndoTex™ NexStent™
The primary objective of this study is to demonstrate the safety of the NexStent for treatment of carotid artery lesions undergoing stenting with adjunctive use of the FilterWire distal embolic protection device.
- Conditions
- Transient Ischemic Attack, Thromboembolic Stroke, Stroke Prevention
- Trial name
- CABERNET (NCT00600327)
- Testing
- EndoTex™ NexStent™, Filter Wire EZ™
- Where
- 19 sites in United States, Argentina and 1 more
- Volunteers
- 488 people
- Sponsor
- Boston Scientific Corporation
Cadasil
CERebrolysin In CADASIL
The objective of this trial is the global risk-benefit assessment of Cerebrolysin as compared to Placebo in patients with genetically proven CADASIL.
- Trial name
- CERICA (NCT05755997)
- Testing
- Cerebrolysin, 0.9 % NaCl
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Ever Neuro Pharma GmbH
Cerebral Aneurysm, Cerebral Aneurysm Unruptured
Parent Artery Reconstruction for Cerebral Aneurysms Using a Novel Flow Diverter With Surface Modification
The primary objective of this trial is to evaluate the safety and efficacy of the cerebral flow diverter in the endovascular treatment of wide-necked cerebral aneurysms
- Trial name
- NCT05774782
- Testing
- Cerebral flow diverter
- Where
- China
- Volunteers
- 143 people
- Sponsor
- Sinomed Neurovita Technology Inc.
Fabry Disease
Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)
This is the first in human treatment with ST-920, an adeno-associated virus (AAV2/6) vector encoding the complementary deoxyribonucleic acid (cDNA) for human a-Gal A.
- Trial name
- NCT04046224
- Testing
- ST-920
- Where
- 18 sites in United States, Australia and 5 more
- Volunteers
- 36 people
- Sponsor
- Sangamo Therapeutics
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Phenprocoumon for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947959
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Standard of care
- Where
- Germany
- Volunteers
- 665,533 people
- Sponsor
- Bayer
Myocardial Infarction
Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack
Restoring blood flow to coronary arteries as quickly as possible is the best way to reduce the damage to the muscle that occurs with a heart attack.
- Trial name
- NCT00093197
- Testing
- KAI-9803 for Injection
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- KAI Pharmaceuticals
Hypertension
Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control.
Patients having uncontrolled or poorly controlled hypertension are at risk of experiencing cardiovascular events such as myocardial infarction or stroke.
- Trial name
- NCT00750113
- Testing
- Nifidipine, Telmisartan, Nifedipine/Telmisartan
- Where
- 43 sites in Italy, Spain
- Volunteers
- 405 people
- Sponsor
- Bayer
Essential Hypertension
PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension
The antihypertensive effect of Amlodipine/Valsartan combination has been evaluated in worldwide populations including Asian patients.
- Trial name
- NCT02058446
- Testing
- Amlodipine/Valsartan
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- TSH Biopharm Corporation Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.